menu
    • menu
    [{"orgOrder":0,"company":"Center Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Verapamil","moa":"Voltage-gated L-type calcium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Center Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Center Laboratories \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Center Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"State Health Center, Hungary","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"HUNGARY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Verapamil","moa":"Voltage-gated L-type calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"State Health Center, Hungary","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"State Health Center, Hungary \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"State Health Center, Hungary \/ Undisclosed"},{"orgOrder":0,"company":"Calosyn Pharma","sponsor":"Health Decisions","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Verapamil","moa":"Voltage-gated L-type calcium channel","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Calosyn Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Calosyn Pharma \/ Health Decisions","highestDevelopmentStatusID":"7","companyTruncated":"Calosyn Pharma \/ Health Decisions"},{"orgOrder":0,"company":"Jaeb Center for Health Research","sponsor":"Juvenile Diabetes Research Foundation | University of Minnesota | DexCom | Medtronic plc | Tandem Diabetes Care, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Verapamil","moa":"Voltage-gated L-type calcium channel","graph1":"Endocrinology","graph2":"Phase III","graph3":"Jaeb Center for Health Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jaeb Center for Health Research \/ Juvenile Diabetes Research Foundation | University of Minnesota | DexCom | Medtronic plc | Tandem Diabetes Care, Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Jaeb Center for Health Research \/ Juvenile Diabetes Research Foundation | University of Minnesota | DexCom | Medtronic plc | Tandem Diabetes Care, Inc."},{"orgOrder":0,"company":"Gillette Children's Specialty Healthcare","sponsor":"Mayo Clinic | Ann & Robert H Lurie Children's Hospital of Chicago | Dartmouth-Hitchcock Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Verapamil","moa":"Voltage-gated L-type calcium channel","graph1":"Neurology","graph2":"Phase II","graph3":"Gillette Children's Specialty Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Gillette Children's Specialty Healthcare \/ Mayo Clinic | Ann & Robert H Lurie Children's Hospital of Chicago | Dartmouth-Hitchcock Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Gillette Children's Specialty Healthcare \/ Mayo Clinic | Ann & Robert H Lurie Children's Hospital of Chicago | Dartmouth-Hitchcock Medical Center"},{"orgOrder":0,"company":"Synerx Pharma, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Verapamil","moa":"Voltage-gated L-type calcium channel","graph1":"Undisclosed","graph2":"Phase I","graph3":"Synerx Pharma, LLC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule, Modified Release","sponsorNew":"Synerx Pharma, LLC \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Synerx Pharma, LLC \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for NCGC00024710-04

    Menu

    NCGC00024710-04

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Jaeb Center for Health Research

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Jaeb Center for Health Research

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Verapamil

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Juvenile Diabetes Research Foundation | University of Minnesota | DexCom | Medtronic plc | Tandem Diabetes Care, Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes

                            Details : Verapamil is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 1.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 18, 2020

                            Lead Product(s) : Verapamil

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Juvenile Diabetes Research Foundation | University of Minnesota | DexCom | Medtronic plc | Tandem Diabetes Care, Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Center Laboratories

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Center Laboratories

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Verapamil

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            R-Verapamil for the Prophylaxis of Episodic Cluster Headache

                            Details : Verapamil is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cluster Headache.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 05, 2014

                            Lead Product(s) : Verapamil

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Calosyn Pharma

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Calosyn Pharma

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Verapamil

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I/ Phase II

                            Sponsor : Health Decisions

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Tolerability, and Efficacy of IA Verapamil in the Treatment of Joint Pain in Subjects With Osteoarthri...

                            Details : Verapamil is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Osteoarthritis, Knee.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 20, 2012

                            Lead Product(s) : Verapamil

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Health Decisions

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Gillette Children's Specialty Healthcare

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Gillette Children's Specialty Healthcare

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Verapamil

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Mayo Clinic | Ann & Robert H Lurie Children's Hospital of Chicago | Dartmouth-Hitchcock Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Verapamil as Therapy for Children and Young Adults With Dravet Syndrome

                            Details : Verapamil is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Epilepsies, Myoclonic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 28, 2012

                            Lead Product(s) : Verapamil

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Mayo Clinic | Ann & Robert H Lurie Children's Hospital of Chicago | Dartmouth-Hitchcock Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Synerx Pharma, LLC

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Synerx Pharma, LLC

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Verapamil

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparative Bioavailability Study of Synerx and Verelan PM 300 mg Verapamil HCl ER Capsules Under Fed Conditio...

                            Details : Verapamil is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 09, 2011

                            Lead Product(s) : Verapamil

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            State Health Center, Hungary

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            State Health Center, Hungary

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Verapamil

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Is Verapamil In TransRadial Interventions OmittabLe?

                            Details : Verapamil is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Coronary Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 26, 2011

                            Lead Product(s) : Verapamil

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth